Titusville, NJ – (March 8, 2018) – Today, the Janssen Pharmaceutical Companies of Johnson & Johnson issued their 2017 Janssen U.S. Transparency Report, available at Janssen.com/2017USTransparencyReport. Joaquin Duato, Executive Vice President and Worldwide Chairman of Pharmaceuticals for Johnson & Johnson, issued the following statement on the release of the report:
“As our second annual Janssen U.S. Transparency Report shows, in 2017 the net price of our medicines in the U.S. decreased while we increased to $7.9 billion our investment in discovering and developing transformational medicines for patients facing some of the world’s most challenging diseases. Our report demonstrates our commitment to responsible business practices that put patients first, including how we invest our resources, price our medicines and help people who need Janssen medicines get access to them.
“We issue this report because we believe open dialogue is essential to developing a more results-based healthcare system that delivers what we all want: greater access to care, at more manageable cost, and, most importantly, better health for all.”
